Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis
company in the US, is pleased to announce that it now has the results of
its survey of more than 1,300 individuals with PTSD, including a large
cohort of veterans. The survey was conducted by Cannabis Science
Advisory Board member Dr. Mitch Earleywine PhD. of the State University
of New York (Albany).
The Company has reported several prospective drugs for FDA clinical
trials. Based on extensive studies and this survey, the Company now has
the substantiated data to for its first application for a PTSD drug
for FDA clinical trials. The Company will now sign a pre-negotiated
contract with a group of FDA specialists based in Colorado to handle the
Company’s first FDA filings.